BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Special BMI Seminar // Neurodegeneration in multiple sclerosis: wh
 at have we learned from pathology?
DTSTART:20171214T150000
DTEND:20171214T160000
DTSTAMP:20260501T173307Z
UID:0a56f54bea90f14bcd802cb4b376205b29930848771f4339b5c461a3
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Jack van Horssen\, University Medical Center (VUmc) of t
 he University Amsterdam \, The Netherlands -  Host: Hilal Lashuel & Laszl
 o Forró (\n\nLaboratory of Nanostructures and Novel Electronic Materials 
 LPMC)\nMultiple Sclerosis (MS) is an inflammatory demyelinating disorder o
 f the central nervous system (CNS)\, initially characterised by acute rela
 pses of neurological dysfunction followed by remission. After a variable p
 eriod this is followed in the majority of patients by a slow and irreversi
 ble progression of neurological dysfunction. Although the acute clinical d
 eficits during early MS can increasingly be prevented with drugs that targ
 et the acute influx of peripheral immune cells\, there are at present no l
 icensed therapeutic agents available that significantly slow the rate of c
 linical progression. The pathology at this advanced stage is characterized
  by the accumulation of chronic demyelinated lesions and axonal loss in th
 e white matter and extensive cortical grey matter pathology. Actually\, ti
 ssue damage in the grey matter is a unique and key component of MS and pro
 vides the best correlate of the rate of progression. Thus\, it is becoming
  generally accepted that neurodegeneration plays a key role in the progres
 sive stage of the disease and drives clinical disease progression. In my t
 alk I will first address key pathological hallmarks of early and advanced 
 MS and in the second part focus on how mitochondrial dysfunction drives ne
 urodegeneration in MS disease progression.\n 
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR